Harvard Bioscience
Logotype for Harvard Bioscience Inc

Harvard Bioscience (HBIO) investor relations material

Harvard Bioscience Q3 2026 earnings summary

Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.
Logotype for Harvard Bioscience Inc
Q3 2026 earnings summary10 Nov, 2026

Executive summary

  • Q3 revenue rose 7.8% YoY to $22.2M, marking a second consecutive quarter of growth; CRO, China and distribution demand supported sales.

  • Adjusted EBITDA was $1.8M; lower-margin product and channel mix pressured margins and led to a cut in FY26 adjusted EBITDA growth guidance.

  • Nine-month revenue increased 4.6% to $65.7M; net loss was $9.0M, with prior-year results affected by a $48.0M goodwill impairment.

Financial highlights

  • Q3 GAAP gross margin was 55.4% vs. 58.4%; adjusted gross margin was 57.1% vs. 59.2%.

  • Operating loss was $1.2M vs. $0.2M operating income; adjusted operating income was $1.2M vs. $1.5M.

  • Adjusted EBITDA was $1.8M vs. $2.0M; adjusted EBITDA margin was 7.9% vs. 9.6%.

  • Net loss was $2.6M vs. $1.2M; GAAP diluted loss per share was $0.58 vs. $0.28, and adjusted diluted loss per share was $0.06 vs. $0.04.

  • Nine-month operating loss was $3.3M vs. $50.3M; nine-month net loss was $9.0M vs. $53.9M.

Outlook and guidance

  • FY26 revenue growth guidance remains 3%–5% and adjusted gross margin guidance 57%–59%; adjusted EBITDA growth guidance was cut to -1%–4% from 6%–10%.

  • Q4 revenue guidance is $23.7M–$25.5M, adjusted gross margin 59%–61%, and adjusted EBITDA $3.8M–$4.2M.

  • Q4 outlook anticipates YoY revenue growth across CMT and NPI platforms, sequential adjusted gross-margin expansion and improving YoY adjusted EBITDA profitability.

  • Management expects gross margin in the 60% range in 2027; ~75% of Project Viking benefits relate to gross margin.

  • Project Viking is expected to save $3M in 2027 and $4M annually from 2028.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
Research faster. Power your platform.

Next Harvard Bioscience earnings date

Logotype for Harvard Bioscience Inc
Q4 202610 Mar, 2027
Harvard Bioscience
Cover every name on your watchlist this earnings season.
Automations, AI chat, and live calls across 16,000+ companies.
Book demo

Next Harvard Bioscience earnings date

Logotype for Harvard Bioscience Inc
Q4 202610 Mar, 2027

AI chat

Ask anything. Verify everything.

Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn more

Automations

Zero in on what matters

Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more

Live audio & transcripts

Be first

Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more

Quartr MCP connects your AI environment to 17K+ public companies

Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more

Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.

Jamie Ross

Investment Manager, GAM Investments

GAM
GAM

Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.

Tom O'Hara

Investment Director

Ciena
Ciena

Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.

Gregg Lampf

VP of Investor Relations

Frequently asked questions

Harvard Bioscience Inc manufactures and sells life sciences equipment used in preclinical research and drug discovery. The company’s products include systems for cellular, molecular, and physiological research, serving academic, pharmaceutical, and biotechnology institutions globally. The company is headquartered in Holliston, Massachusetts, and its shares are listed on the NASDAQ.